Alzheimer's Early Detection and its Combination Drug

will help you get better and stay healthier.

1. Combination Alzheimer's disease (AD) drug (NV909AD) targeting both β-amyloid protein and neuroinflammation, supported by the combined β-amyloid protein and neuroinflammation hypothesis

β-Amyloid protein and neuroinflammation are the hallmarks of AD pathogenesis in the brain. 

NV909AD is the first combination AD drug targeting both β-amyloid protein

and neuroinflammation. NV909AD would increase the drug effectiveness to slow down cognitive

decline of Alzheimer’s patients, compared with mono β-amyloid antibody-based drug such as

Biogen's lecanemab and Eli lilly's donanemab. NV909AD would be a potential strategy to

overcome the limited effectiveness of anti-Aβ antibody therapeutic drug.

The company plans to test its efficacy and safety in an attempt to increase clinical trial 


2. Cancer immunotherapeutic drug (NV901C) targeting abnormal extracellular matric (ECM)-associated breast cancer antigen (ECM-BrCA) for the treatment of cancer patients with breast cancer.

ECM-BrCA targeting therapeutic strategies are designed to neutralize abnormal ECM-BrCA in an effort to block tumor growth and metastasis in breast cancer. These strategies include ECM-BrCA neutralizing antibody, treatment dose, method, safety, efficacy, etc.

                         Early Diagnosis of Alzheimer's Disease                           

( Bioassay to measure β-amyloid protein autoantibody and 

total antioxidant capacity (TAC) in blood serum)

Testing service is now available.

(At-Home blood collection kit with lancet and shipping are free.)

Please inquire Request Form through Contact US,

Or fill Request Form through Ordering.



                      Molecular Structure of phospho-MAPK 


A rapid test of Redox colorimetric TAC assay kit  by using a tiny amount of whole blood from the fingerstick serum  is now available in the marketplace as a format of a point-of care application. (Aug. 2019) 

Cancer immunotherapeutic drug (NV901C) targeting abnormal ECM-BrCA for the treatment of breast cancer patients. (Sept. 2021)

Combination AD drug (NV909AD) is developed to target both β-amyloid protein and neuroinflammation. (April 2022)


New AD combination biomarkers, 

β-amyloid autoantibody and total antioxidant 

capacity (TAC) are specific for early AD diagnosis. (Oct. 2022) 

About Us

Vanc Biotechnology is committed to the research and development of diagnosis and drugs for cancer, 

alzheimer's diseases.


Our commitment is to develop the preventive screening test from human blood serum or plasma for 

the early detection and diagnosis of human cancers, and also alzheimer's diseases. We believe that our efforts will contribute to the better and healthier life.


Along this line, Vanc Biotechnology has been participated in the development of new serum biomarkers 

for early cancers and Alzheimer's diseases.




110-1110 E27th St, North Vancouver, B.C.